APOTEX has lost its Federal Court
appeal against a 2008 Court
decision which restrained it from
supplying its generic leflunomide
product for the treatment of
psoriatic arthritis.
Leflunomide is supplied in
Australia by Sanofi-Aventis under
the names Arava and Arabloc for
the treatment of psoriasis.
In its appeal, Apotex argued that
a claim in Sanofi’s leflunomide
patent did not support the order
which was made at first instance,
because it is a method of
preventing or treating only the
specified ailment psoriasis.
Apotex also argued that the
patent was invalid, primarily
because of want of novelty.
After considering the claims, the
Federal Court dismissed the appeal
in a unanimous decision, and
ordered Apotex to pay Sanofi’s
court costs.The above article was sent to subscribers in Pharmacy Daily's issue from 26 Jul 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Jul 12
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.